When the US Food and Drug Administration (FDA) approved Semglee, the first interchangeable biosimilar insulin, the agency pitched it as having the potential to be less costly than insulins currently ...

The pharmaceutical Eli Lilly and Company announced Wednesday that it will reduce some insulin prices by 70% and expand access to a program that caps prices at $35 per month. The company says its ...

Civica plans to sell its insulin at no more than $30 per vial. By comparison, the branded versions of insulin can cost four times that amount—and even more for those who are uninsured. Those high ...

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...